mercaptoethanol has been researched along with Urinary Tract Diseases in 5 studies
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized study in 20 patients with cancer was carried out to test the clinical efficacy of sodium-2-mercaptoethane sulfonate (ASTA D-7093; mesnum) as an agent to prevent urotoxic side effects (in particular, hemorrhagic cystitis) during cytostatic therapy with the oxazaphosphorines cyclophosphamide and ifosfamide." | 2.65 | Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. ( Brock, N; Burkert, H; Günther, U; Hoefer-Janker, H; Klein, HO; Mitrenga, D; Scheef, W; Schnitker, J; Voigtmann, R, 1979) |
| "One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX)." | 1.28 | Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. ( Falkson, CI; Falkson, G; Falkson, HC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brock, N | 2 |
| Schnitker, J | 2 |
| Scheef, W | 1 |
| Klein, HO | 1 |
| Burkert, H | 1 |
| Günther, U | 1 |
| Hoefer-Janker, H | 1 |
| Mitrenga, D | 1 |
| Voigtmann, R | 1 |
| Holoye, PY | 1 |
| Glisson, BS | 1 |
| Lee, JS | 1 |
| Dhingra, HM | 1 |
| Murphy, WK | 1 |
| Umsawasdi, T | 1 |
| Levy, JK | 1 |
| Jeffries, D | 1 |
| Raber, MN | 1 |
| Hong, WK | 1 |
| Falkson, CI | 1 |
| Falkson, HC | 1 |
| Falkson, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mercaptoethanol and Urinary Tract Diseases
| Article | Year |
|---|---|
[Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
Topics: Hematuria; Humans; Mercaptoethanol; Mesna; Phosphoramide Mustards; Urologic Diseases | 1982 |
Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
Topics: Clinical Trials as Topic; Cystitis; Drug Therapy, Combination; Hematuria; Humans; Male; Mercaptoetha | 1979 |
3 other studies available for mercaptoethanol and Urinary Tract Diseases
| Article | Year |
|---|---|
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cystitis; Erythrocyte Count; Ifosfamide; Mercaptoe | 1980 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans | 1990 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi | 1989 |